Genmab Announces Positive Phase 3 EPCORE FL-1 Trial Results for Epcoritamab in R/R Follicular Lymphoma
ByAinvest
Thursday, Aug 7, 2025 10:32 am ET1min read
GMAB--
Genmab's Phase 3 EPCORE FL-1 trial met dual primary endpoints for relapsed/refractory follicular lymphoma (FL), demonstrating a 95.7% overall response rate and a 79% reduction in progression-free survival. The results will serve as the basis for global regulatory submissions. The US FDA has accepted the supplemental Biologics License Application for priority review, with a target action date of November 30, 2025. If approved, epcoritamab plus rituximab and lenalidomide would be the first bispecific antibody combination regimen available for second-line treatment in R/R FL.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet